WO2012005550A3 - 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 - Google Patents

담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 Download PDF

Info

Publication number
WO2012005550A3
WO2012005550A3 PCT/KR2011/005033 KR2011005033W WO2012005550A3 WO 2012005550 A3 WO2012005550 A3 WO 2012005550A3 KR 2011005033 W KR2011005033 W KR 2011005033W WO 2012005550 A3 WO2012005550 A3 WO 2012005550A3
Authority
WO
WIPO (PCT)
Prior art keywords
gallbladder carcinoma
treating
carcinoma
metastasis
pharmaceutical composition
Prior art date
Application number
PCT/KR2011/005033
Other languages
English (en)
French (fr)
Other versions
WO2012005550A2 (ko
Inventor
홍효정
김진만
정문식
윤현호
Original Assignee
강원대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 강원대학교산학협력단 filed Critical 강원대학교산학협력단
Publication of WO2012005550A2 publication Critical patent/WO2012005550A2/ko
Publication of WO2012005550A3 publication Critical patent/WO2012005550A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법에 관한 것이다. 본 발명의 담낭암 세포 표면의 L1CAM 단백질을 인식하며 담낭암 조직에 특이적으로 결합하는 항체 또는 siRNA, shRNA 또는 안티센스 올리고뉴클레오티드 및 이를 포함하는 약제학적 조성물은 담낭암의 성장, 침윤 및 이동을 억제 및 세포 사멸을 유도할 수 있으므로, 보다 안전하면서도 효과적인 담낭암의 예방 및 치료에 널리 활용될 수 있을 것이다.
PCT/KR2011/005033 2010-07-08 2011-07-08 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 WO2012005550A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100066055 2010-07-08
KR10-2010-0066055 2010-07-08

Publications (2)

Publication Number Publication Date
WO2012005550A2 WO2012005550A2 (ko) 2012-01-12
WO2012005550A3 true WO2012005550A3 (ko) 2012-04-26

Family

ID=45441681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/005033 WO2012005550A2 (ko) 2010-07-08 2011-07-08 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법

Country Status (2)

Country Link
KR (1) KR101271964B1 (ko)
WO (1) WO2012005550A2 (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
HUE027332T2 (en) 2008-08-05 2016-09-28 Toray Industries Cancer Detection Method
PT2532743E (pt) 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
US9796775B2 (en) 2011-08-04 2017-10-24 Toray Industries, Inc. Method for detecting pancreatic cancer
PT3351630T (pt) 2011-08-04 2019-12-30 Toray Industries Composição farmacêutica compreendendo anticorpos anti caprin-1 para tratar e/ou prevenir o cancro
JP6003650B2 (ja) 2011-08-04 2016-10-05 東レ株式会社 膵臓癌の治療及び／又は予防用医薬組成物
RU2633505C2 (ru) 2012-02-21 2017-10-12 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
CA2864869C (en) 2012-02-21 2021-10-19 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX360208B (es) 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AU2013223137B2 (en) 2012-02-21 2017-10-19 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PL2832365T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
JP6107655B2 (ja) * 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
HUE043162T2 (hu) 2012-07-19 2019-08-28 Toray Industries Eljárás rák detektálására
CN104471404B (zh) 2012-07-19 2017-03-01 东丽株式会社 癌的检测方法
JP6447130B2 (ja) 2013-08-09 2019-01-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物
KR20180079232A (ko) * 2016-12-30 2018-07-10 강원대학교산학협력단 L1cam 단백질에 특이적으로 결합하는 항체 및 피리미딘 유사체 및/또는 플라틴계 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100931976B1 (ko) * 2006-08-23 2009-12-15 한국생명공학연구원 담도암 치료용 약제학적 조성물 및 이를 이용한 담도암의성장, 전이 억제 및 치료 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100060351A (ko) * 2008-11-27 2010-06-07 한국생명공학연구원 Ｌ１ｃａｍ의 활성 또는 발현을 억제하는 물질 및 항암제를포함하는 항암용 조성물
KR101501736B1 (ko) * 2008-12-05 2015-03-12 한국생명공학연구원 인간 및 마우스에서 발현하는 ｌ1ｃａｍ에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100931976B1 (ko) * 2006-08-23 2009-12-15 한국생명공학연구원 담도암 치료용 약제학적 조성물 및 이를 이용한 담도암의성장, 전이 억제 및 치료 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S. SEBENS MUERKOSTER ET AL.: "Drug-induced expression of the cellular adhension molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells", ONCOGENE, vol. 26, no. 19, 2007, pages 2759 - 2768, XP002436286, DOI: doi:10.1038/sj.onc.1210076 *
SHIDENG BAO ET AL.: "Targeting cancer stem cells through L1CAM suppresses glioma growth", CANCER RESEARCH, vol. 68, no. 15, 2008, pages 6043 - 6048 *

Also Published As

Publication number Publication date
WO2012005550A2 (ko) 2012-01-12
KR20120005412A (ko) 2012-01-16
KR101271964B1 (ko) 2013-06-07

Similar Documents

Publication Publication Date Title
WO2012005550A3 (ko) 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
WO2009109911A8 (en) Methods of treating chronic pain
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
WO2013059396A3 (en) Treatment of cancer with tor kinase inhibitors
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
WO2012145183A3 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2012062925A3 (en) Compounds and methods for treating pain
WO2010056737A3 (en) Methods and compositions involving mirnas in cancer stem cells
WO2011146568A8 (en) Predicting response to a her inhibitor
SG169988A1 (en) Rnai inhibition of alpha-enac expression
WO2007143086A3 (en) Delivery method
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
WO2012138789A3 (en) Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
WO2012006181A3 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
WO2009158374A3 (en) Inhibitors of akt activity
WO2009143292A9 (en) Method of treating pneumoconiosis with oligodeoxynucleotides
WO2014062878A3 (en) Treatment of prostate cancer with tor kinase inhibitors
TWI369590B (en) Treatment liquid for resist substrate, and method of treating resist substrate using the same
WO2009127414A3 (en) Inhibition of angiogenesis and tumor metastasis
WO2012139043A3 (en) Selective neuronal nitric oxide synthase inhibitors
WO2010054328A3 (en) Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
WO2011011061A3 (en) Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy
CA2810119C (en) Clec14a inhibitors
WO2010085151A3 (en) Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil
WO2009044153A3 (en) Inhibitors and uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11803836

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11803836

Country of ref document: EP

Kind code of ref document: A2